SNP genotyping market forecast highlighting trends and expansion potential

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Single Nucleotide Polymorphism (SNP) Genotyping Market Progress Between 2026 And 2030?

The single nucleotide polymorphism (snp) genotyping market has witnessed substantial growth in recent years. It is projected to increase from $12.34 billion in 2025 to $14.69 billion in 2026, achieving a compound annual growth rate (CAGR) of 19.1%. This historic expansion can be attributed to several factors, including early limitations in genotyping capabilities, a rising demand within research, the significant cost associated with genomic analysis, increasing collaborations among research laboratories, and its initial integration into pharmacogenomics.

The single nucleotide polymorphism (snp) genotyping market size is projected to experience substantial expansion in the coming years. It is anticipated to grow to $29.74 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 19.3%. The drivers for this growth during the forecast period include the development of high-throughput SNP platforms, increasing adoption in personalized medicine, integration with AI for predictive analysis, expansion into clinical diagnostics, and the growth in agricultural genomics applications. Major trends anticipated in the forecast period are the integration with pharmacogenomics, an increase in disease risk prediction, growing use in agriculture and animal breeding, the adoption of microarray-based genotyping, and a rise in point-of-care SNP testing.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12569&type=smp

What Key Drivers Are Fueling The Growth Of The Single Nucleotide Polymorphism (SNP) Genotyping Market?

The single nucleotide polymorphism (SNP) genotyping market is projected to grow due to the increasing burden of chronic conditions. Chronic conditions are health issues that persist for a year or longer, demanding continuous medical care, restricting daily activities, or both. With the rising occurrence of these diseases, single-nucleotide polymorphism (SNP) genotyping becomes vital for identifying genetic predispositions and advancing personalized medicine. For example, as reported in April 2025 by the Centers for Disease Control and Prevention (CDC), a US federal agency, approximately 194 million U.S. adults, or 76.4%, stated having at least one chronic condition in 2023. The prevalence reached 59.5% for young adults, 78.4% for midlife adults, and 93.0% for older adults. Thus, the escalating impact of chronic conditions serves as a significant driver for the growth of the single nucleotide polymorphism (SNP) genotyping systems market.

What Are The Key Segment Divisions In The Single Nucleotide Polymorphism (SNP) Genotyping Market Segment Structure?

The single nucleotide polymorphism (snp) genotyping market covered in this report is segmented –

1) By Product: Consumables, Instruments, Services

2) By Technology: TaqMan SNP Genotyping, Mass Array SNP Genotyping, SNP Gene Chip Arrays, Other Technologies

3) By Application: Animal Genetics, Plant Improvement, Diagnostic Research, Pharmaceuticals And Pharmacogenomics, Agricultural Biotechnology, Other Applications

Subsegments:

1) By Consumables: Reagents And Kits, DNA Probes, Microarrays

2) By Instruments: SNP Genotyping Platforms, Sequencers, PCR Machines

3) By Services: SNP Genotyping Services, Data Analysis Services, Consultation Services

What Trends Are Influencing The Single Nucleotide Polymorphism (SNP) Genotyping Market?

Companies active in the single nucleotide polymorphism (SNP) genotyping market are enhancing their profitability by developing biomarkers specifically useful in detecting coronary heart disease. Single nucleotide polymorphism (SNP) biomarkers for coronary heart disease (CHD) detection represent distinct genetic variations identified through genomic studies that are linked to an elevated risk or susceptibility to CHD. As an illustration, in February 2023, Cardio Diagnostics, a US-based biotechnology company, introduced PrecisionCHD. This AI-driven blood test employs a combination of epigenetic (DNA methylation) and genetic (single nucleotide polymorphism) biomarkers to identify CHD. The test leverages a machine-learning model to achieve over 75% sensitivity for both genders, offering a non-invasive alternative for blood sample collection either in a clinical setting or at home. This approach negates the need for traditional examinations such as stress tests, ensuring objectivity by relying exclusively on biomarkers rather than information provided by the patient.

Which Organizations Are Engaged In The Single Nucleotide Polymorphism (SNP) Genotyping Market?

Major companies operating in the single nucleotide polymorphism (snp) genotyping market are Thermo Fischer Scientific Inc, Danaher Corporation, Roche Diagnostics Corporation, GE HealthCare Technologies Inc, Eurofins Genomics LLC, Beckman Coulter Inc, Bio-Rad Laboratories Inc, Qiagen N.V, Sigma-Aldrich Corporation, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Promega Corporation, GenScript Biotech Corporation, Integrated DNA Technologies Inc, LGC Ltd, Sequenom Inc, Fluidigm Corporation, Oxford Gene Technology, Affymetrix Inc, PREMIER Biosoft International Inc, Rubicon Genomics, Xcelris Genomics, Douglas Scientific LLC, Golden Helix Inc

Get The Full Single Nucleotide Polymorphism (SNP) Genotyping Market Report:

https://www.thebusinessresearchcompany.com/report/single-nucleotide-polymorphism-snp-genotyping-global-market-report

Where Is The Single Nucleotide Polymorphism (SNP) Genotyping Market Primarily Concentrated By Region?

North America was the largest region in the single nucleotide polymorphism (SNP) genotyping market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single nucleotide polymorphism (snp) genotyping market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Single Nucleotide Polymorphism (SNP) Genotyping Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/single-nucleotide-polymorphism-snp-genotyping-global-market-report

Browse Through More Reports Similar to the Global Single Nucleotide Polymorphism (SNP) Genotyping Market 2026, By The Business Research Company

Genotyping Market Report 2026

https://www.thebusinessresearchcompany.com/report/genotyping-global-market-report

Genotyping Assay Market Report

https://www.thebusinessresearchcompany.com/report/genotyping-assay-global-market-report

Genomics Market Report

https://www.thebusinessresearchcompany.com/report/genomics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795